Weight-loss wars: $10bn hostile battle pits Pfizer against Novo Nordisk
Two groups fight for edge in one of the most lucrative drug classes in pharmaceutical industry history
Related reading
Battle for obesity biotech Metsera heats up as Pfizer sues to block rival bid
FTC fast-tracks antitrust approval of earlier deal in sign Washington could weigh in on takeover battle with Novo Nordisk
Battle for weight-loss supremacy shifts from jabs to pills
Novo Nordisk’s Wegovy tablet offers Danish drugmaker window to win back market share from Eli Lilly
Pfizer wins $10bn bidding war for weight-loss start-up Metsera
Biotech says it opted for revised offer from US pharma company after rival Novo bid raised antitrust concerns
Pharma just ‘scratching the surface’ of weight-loss drug market
Novo Nordisk chief estimates industry reaching only 15% of potential customers at most
Triple dose of Novo Nordisk drug delivers 19% weight loss in trials
Danish pharma group seeks to broaden options and stay competitive with Eli Lilly
How Novo Nordisk lost its lead in the weight loss race
Drugmaker struggled to adapt to very high demand and a market where celebrities are more influential than doctors